Tofacitinib ' s Cancer, CV Risks Outlined in Older RA Patients Tofacitinib ' s Cancer, CV Risks Outlined in Older RA Patients

Using tofacitinib to treat rheumatoid arthritis increases the risk of developing cancer by 48% vs a TNF inhibitor, according to a safety analysis published in The New England Journal of Medicine.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news